What Rezo Therapeutics does

Rezo Therapeutics is a privately held, clinical-stage-preclinical biotechnology company founded in November 2022 and headquartered at 455 Mission Bay Blvd South in San Francisco's Mission Bay district. The company develops precision therapeutics, with an initial focus on solid tumor oncology, by applying an integrated disease network mapping approach to identify novel, druggable protein-protein interaction targets that are difficult to discover through traditional siloed methods.

The company's core product is the Sequence to Systems to Drugs (SSD) platform, which combines proteomics, genetics, structural biology, chemistry, and bioinformatics with proprietary AI/ML models — including a Protein-Protein Interaction (PPI) Foundation Model and a multimodal Network AI model — to construct comprehensive maps of molecular disease networks and prioritize druggable interfaces within protein complexes. The platform originated from two decades of research at UCSF's Quantitative Biosciences Institute (QBI) under co-founder Nevan Krogan, and has been extended through a March 2026 technical collaboration with NVIDIA (Boltz-1 CP, Context Parallelism via Fold-CP Framework) enabling structural prediction of protein complexes up to 6,500 residues on 16 H100 GPUs. Rezo has approximately 30-50 employees across leadership, computational biology, proteomics, medicinal chemistry, and operations.

Rezo is pre-revenue. Its go-to-market is sales-led and partnership-driven, targeting pharmaceutical and biotech counterparties for co-development and licensing of pipeline programs; future revenue is expected to come from development milestones, licensing royalties, and eventual product commercialization rather than near-term product sales. The company launched with a $78 million Series A in November 2022, led by SR One, a16z Bio + Health, and Norwest Venture Partners, with participation from Eli Lilly, Alexandria Venture Investments, SV Angel, Liquid 2 Ventures, and Hawktail.

Name

Rezo Therapeutics

Legal name

Rezo Therapeutics Inc.

Website

https://rezotx.space

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Rezo Therapeutics is a preclinical, pre-revenue biotech that uses an integrated proteomics, genetics, structural biology, chemistry, and bioinformatics platform with proprietary AI/ML models to map molecular disease networks and identify druggable protein-protein interaction targets for precision oncology therapeutics, out-licensed to pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Precision Therapeutics Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Precision drug discovery
• Disease network mapping
• Protein-protein interactions
• Computational biology platform
• Precision oncology therapeutics

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Development and Licensing: Pre-revenue biotech company developing a pipeline of precision therapeutics. Revenue will be generated through development milestones, licensing deals with pharmaceutical partners, and eventual product commercialization. Initial focus on oncology with plans to expand to additional therapeutic areas.
2. Platform Partnerships and Collaborations: Technology and research collaborations with pharma partners leveraging the disease network mapping platform for target discovery and drug development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Rezo Therapeutics develops precision therapeutics using its Sequence to Systems to Drugs (SSD) platform, which integrates proteomics, genetics, structural biology, chemistry, and bioinformatics with proprietary AI/ML models to create comprehensive maps of molecular disease networks. The company identifies novel, druggable protein-protein interaction targets and advances a pipeline of mutation-specific precision medicines, with an initial focus on solid tumor oncology, pursuing co-development and licensing partnerships with pharmaceutical companies.

Product overview

Rezo Therapeutics operates as a single-platform biotechnology company with its core offering being the Sequence to Systems to Drugs (SSD) Platform—an integrated disease network mapping system. The platform is enhanced by proprietary AI/ML models including a PPI Foundation Model for protein-protein interaction prediction and a Multimodal Network AI model for identifying novel protein complexes. These components work together to map molecular disease networks, identify druggable targets, and accelerate precision therapeutic discovery, with an initial focus on oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• Sequence to Systems to Drugs (SSD) Platform An integrated disease network mapping platform that combines proteomics, genetics, structural biology, chemistry, and bioinformatics data with AI/ML to create comprehensive maps of molecular disease networks and identify novel, druggable targets for precision therapeutics. The platform is targeted at pharmaceutical and biotech companies seeking novel drug targets.

Quantifiable outcome

• Over 5-fold enrichment of structurally viable protein complexes vs STRING Baseline, and ~3-fold vs stricter STRING Clique set, using Rezo's Network AI model validated with Boltz-1 CP structural predictions.
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• NVIDIAcoreTechnology or Integration · 16 March 2026Technical collaboration with NVIDIA BioNeMo Team to implement Context Parallelism (Fold-CP Framework) into Boltz-1 (Boltz-1 CP) for large-scale protein complex structure prediction. Rezo's PPI foundation model combined with NVIDIA's computational architecture enables prediction of structures for complexes up to 6,500 residues, covering 93% of the CORUM database. Collaboration also included addition of cuEquilibrance. This is a co-development partnership for computational biology infrastructure.
• University of California, San Francisco (UCSF)coreStrategic or Co-development PartnerRezo's platform is based on technology from UCSF's Quantitative Biosciences Institute (QBI). Co-founder Nevan Krogan is Director of QBI and Professor at UCSF. Multiple co-founders hold positions at UCSF (Kevan Shokat, Natalia Jura, Sourav Bandyopadhyay). The academic partnership provides ongoing scientific collaboration and talent pipeline.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery company combining high-throughput biology with machine learning to map gene–function relationships. It is comparable to Rezo as a broad incumbent in AI/ML-enabled therapeutic discovery, though Recursion operates at significantly larger scale with public-market capital and a more diversified pipeline.
• Schrödinger, Inc. Schrödinger provides physics-based computational chemistry and machine learning software used across the pharma industry for molecular design and property prediction. It is a broad incumbent comparable to Rezo's computational biology infrastructure, with overlapping focus on structure prediction and lead optimization.
• Isomorphic Labs: Isomorphic Labs is Alphabet/DeepMind's commercial drug-discovery spinout applying AlphaFold-derived structural biology and AI to small-molecule design. It is comparable to Rezo as a frontier AI-structural biology platform pursuing pharma partnerships, with substantially greater capital and compute resources.

Emerging players

• Xaira Therapeutics: Xaira is an AI-native biotech launched with >$1B in 2024 to apply foundation models to drug discovery. It is an emerging but very well-capitalized peer with overlapping scope in AI-driven target identification and antibody/protein design.
• Atomwise: Atomwise uses AI for small-molecule hit discovery and has multiple pharma collaborations. It is an emerging player with partial overlap to Rezo's platform model, though Atomwise is more focused on virtual screening than on PPI network mapping.

Direct peers

• Insitro: Insitro uses machine learning on large-scale cellular and multi-omics data to predict drug behavior and identify targets. It is directly comparable to Rezo as an AI/ML-driven platform company focused on disease-network biology and target discovery, with strong partnerships with pharma.
• Revolution Medicines: Revolution Medicines develops tri-complex inhibitors targeting oncogenic RAS variants, founded by Rezo co-founder Kevan Shokat. It is a direct peer in structure-guided PPI/tri-complex oncology drug discovery, with shared scientific lineage and Shokat's continued involvement.
• Generate Biomedicines: Generate Biomedicines applies generative AI to programmable biology for protein-based therapeutic design. It is a direct peer in AI/ML-enabled biologic drug discovery with a similar platform-company GTM model targeting pharma partnerships.
• Nurix Therapeutics: Nurix develops targeted protein degradation drugs leveraging E3 ligase biology, with a similar oncology/inflammation focus. It is comparable as a peer biotech in protein-interaction-based drug discovery; Rezo's CSO Cristiana Guiducci previously served as SVP of Oncology and Immunology Research at Nurix.
• Maze Therapeutics: Maze Therapeutics applies functional genomics and computational biology to identify genetic variants causal for disease and develop precision medicines. It is a direct peer in AI/ML-enabled genetics-driven target discovery, with overlapping Bay Area talent (Rezo's SVP of Drug Discovery previously headed Molecular Sciences at Maze).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rezotx

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds1 record

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rezo Therapeutics